Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s476. https://doi.org/10.25251/skin.8.supp.476